Summary: Eli Lilly’s stock has performed well in the market, boosted by strong fundamental results
Summary: Eli Lilly’s stock is hitting new all-time highs as earnings continue to grow at
Summary: Obesity affects a significant percentage of adults around the world and is linked to
Summary: The Nasdaq’s 15-year period of zero returns highlights the importance of valuation in the
Summary: Eli Lilly and Company reported a superb Q2, triggering a sharp price rally and
Summary: Eli Lilly and Company reported Q2 results exceeding expectations and raised 2023 revenue guidance.
Summary: Eli Lilly and Company’s Q2 2023 earnings were boosted by strong sales growth of
Summary: Pharmaceutical company Eli Lilly and Company is purchasing biotech firm Sigilon Therapeutics, Inc. for
Summary: Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV’s Humira. This
Summary: Biogen, Eisai, and Eli Lilly’s Alzheimer’s drugs have shown little efficacy, particularly in non-APOE4